Moto Stocks

Wynn Resorts (WYNN) Downgraded by UBS

WYNN, Wynn Resorts Ltd.

** WYNN was downgraded from Buy to Neutral by Brokerage Firm UBS

WYNN , together with its subsidiaries, engages in the development, ownership, and operation of destination casino-resorts.

More about WYNN at www.wynnresorts.com

********

The Internet is likely to continue to play a large role in individuals' lives in the foreseeable future. Whether personal computers remain the dominant method of accessing the Internet, some form of global communication network will likely be a reality for many generations, creating effective avenues of sending advertising messages to consumers in the community and around the world .

Crown Equity Holdings Inc., (CRWE) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

CRWE ’s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

CRWE ’s division CRWE AD-Services ( www.crwe-adservices.com ), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.

More about CRWE at www.crownequityholdings.com .

********

Read Full Disclaimer at: http://doubleinstocks.com/disclaimer

Gilead Sciences to Acquire YM Biosciences (YMI) fo

YMI, YM BioSciences Inc.

** Gilead Sciences, Inc. and YMI reported that the companies have signed a definitive agreement under which Gilead will acquire YMI for U.S.$2.95 per share in cash.

The transaction has received the unanimous approval of YMI 's Board of Directors, and values YMI at approximately U.S.$510 million, with YMI reporting C$125.5 million in cash and cash equivalents as of September 30, 2012. Gilead plans to fund the acquisition with cash on hand.

The transaction is expected to close in the first quarter of 2013.

YMI is a drug-development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers.

More about YMI at www.ymbiosciences.com

********

Read Full Disclaimer at: http://doubleinstocks.com/disclaimer

Aegion Corp. (AEGN) Gets $ Fibrwrap(R) Pipe Re

AEGN, Aegion Corporation

** AEGN reported that its subsidiary, Fyfe Hong Kong Limited, has received a contract valued at $8.5 million for the rehabilitation of potable water pipelines, ranging from 35-inches to 47-inches in diameter, located in Hong Kong for the Government of Hong Kong Water Supplies Department.

This award is in addition to the Fyfe Hong Kong project announced in September 2012 valued at $12.9 million.

Fyfe Hong Kong will install its patented Tyfo(R) Fibrwrap(R) system, a fiber reinforced polymer material that repairs, strengthens and retrofits pressure pipelines.

AEGN is a global leader in infrastructure protection, providing proprietary technologies and services to protect against the corrosion of industrial pipelines and for the rehabilitation and strengthening of sewer, water, energy and mining piping systems and buildings, bridges, tunnels and waterfront structures.

More about AEGN at www.aegion.com .

********

Read Full Disclaimer at: http://doubleinstocks.com/disclaimer

Geron (GERN), Positive Data from Phase 2 Study of

GERN, Geron Corporation

** GERN reported positive clinical results from the Phase 2 trial of imetelstat, GERN `s first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs).

The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, by Prof. Dr. med. Gabriela M. Baerlocher of the University Hospital and University of Bern, Switzerland, and a principal investigator of the trial.

To view the presentation slides, please visit www.geron.com/PDFs/Geron-Imetelstat-ETPh2-ASH-2012.pdf .

GERN is a biopharmaceutical company developing first-in-class therapies for cancer, including its telomerase inhibitor, imetelstat.

More about GERN at www.geron.com .

********

Read Full Disclaimer at: http://doubleinstocks.com/disclaimer

Northrop Grumman (NOC) Signs Strategic Alliance wi

NOC, Northrop Grumman Corporation

** Wynyard Group, the specialists in intelligence-led solutions for protecting companies and countries from threat, crime and corruption, has entered into a strategic alliance with NOC to market and develop joint offerings to the US public sector and commercial markets.

NOC will leverage its significant market presence and expertise within the US Federal Government to jointly offer the portfolio of Wynyard's solutions.

NOC provides products, services, and solutions in aerospace, electronics, information systems, and technical services worldwide.

More about NOC at www.northropgrumman.com

********

Read Full Disclaimer at: http://doubleinstocks.com/disclaimer